VSY Biotechnology’s Sinusoidal Vision Technology (SVT®) Secures U.S. Patent Grant

Andreas C. Kühnel, Managing Director at VSY Biotechnology announced that the company’s innovative Sinusoidal Vision Technology (SVT®) has received its U.S. patent from the United States Patent and Trademark Office. This significant milestone is a testament to the company's commitment to pushing the boundaries of ophthalmic innovation and signifies its leadership in optic technologies. 

Sinusoidal Vision Technology (SVT®) is a groundbreaking technology that provides a spectacle-free vision for cataract patients. The technology provides a unique solution to improve vision technology by eliminating the disadvantages of blazed/kinoform diffraction gratings requiring a superposition of 2 different carriers in traditional trifocal IOLs. 

The SVT® technology is incorporated in AcrivaUD Trinova Pro C Pupil Adaptive®, the world's first and only sinusoidal trifocal intraocular lens which combines with Pupil Adaptive Design. Thanks to its advanced Sinusoidal Vision Technology (SVT®), Acriva Trinova Pro C Pupil Adaptive® distributes effective and efficient light energy between three foci according to different light conditions and pupil sizes to maximize the wide visual range.

The Sinusoidal Vision Technology (SVT®), developed by VSY Biotechnology, has received validation from 11 European countries and has patent registration in many countries worldwide, including China and Russia. Additionally, VSY Biotechnology has patent registration and new applications pending in different parts of the world for many products developed in ophthalmology. 

The company's patented technologies are not only innovative but are also designed to enhance the quality of life for patients. The success of SVT® underscores the company's commitment to pushing the boundaries of what is possible in the field of ophthalmology and providing patients with access to the most advanced treatments. 

In addition to its current products, VSY Biotechnology has also plans two major product launches in its pipeline. The Enova ADVANCED Extended Vision IOL will be launched at the 2023 ESCRS Congress in Vienna. Furthermore, a new intraocular lens that offers a comprehensive solution for presbyopia, named Enova MAESTRO, featuring SVT® technology, will be introduced to the market in January 2024. Both of these innovative lenses will be available in a 100% glistening-free hydrophobic platform, underscoring VSY Biotechnology's unwavering commitment to state-of-the-art technology and optimal performance. 

VSY Biotechnology has exciting plans to announce further advancements and innovations in the field of ophthalmology in the near future.